Stem cell transplantation for autoimmune disease: progress and problems

被引:19
作者
Furst, DE [1 ]
机构
[1] Univ Calif Los Angeles, Sch Med, Div Rheumatol, Rehabil Ctr, Seattle, WA 98101 USA
关键词
D O I
10.1097/00002281-200205000-00004
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
The current status of stem cell transplantation in rheumatoid arthritis, juvenile chronic arthritis, systemic lupus erythematosus, and systemic sclerosis are reviewed. From a large European bone marrow transplant registry, a birds' eye view of stem cell transplantation for autoimmune disease can be obtained. Among 43 rheumatoid arthritis patients, 35 juvenile chronic arthritis patients, 34 systemic lupus erythematosus patients, and 58 systemic sclerosis patients who underwent stem cell transplantation, initial responses in most patients were good to excellent. Although initial transplant related mortality was low for rheumatoid arthritis, somewhat higher rates for juvenile chronic arthritis, systemic lupus erythematosus, and systemic sclerosis may be falling with modifications in the stem cell transplantation regimens. In rheumatoid arthritis and systemic lupus erythematosus treatment, the criteria for patient selection are still not clear and the therapeutic regimens for stem cell transplantation (and whether follow-up treatment is necessary) are not fully defined. In juvenile chronic arthritis, responses are encouraging although little fully published data beyond that from the European Bone Marrow Transplant Registry exist. In systemic sclerosis, criteria for patient selection and a limited number of stem cell transplantation regimens have been agreed on and controlled trials are underway. (C) 2002 Lippincott Williams Wilkins, Inc.
引用
收藏
页码:220 / 224
页数:5
相关论文
共 28 条
[1]
ABUSHAKRA M, 1995, J RHEUMATOL, V22, P1265
[2]
Phase I/II trial of autologous stem cell transplantation in systemic sclerosis:: procedure related mortality and impact on skin disease [J].
Binks, M ;
Passweg, JR ;
Furst, D ;
McSweeney, P ;
Sullivan, K ;
Besenthal, C ;
Finke, J ;
Peter, HH ;
van Laar, J ;
Breedveld, FC ;
Fibbe, VE ;
Farge, D ;
Gluckman, E ;
Locatelli, F ;
Martini, A ;
van den Hoogen, F ;
van de Putte, L ;
Schattenberg, AVN ;
Arnold, R ;
Bacon, PA ;
Emery, P ;
Espigado, I ;
Hertenstein, B ;
Hiepe, F ;
Kashyap, A ;
Kötter, I ;
Marmont, A ;
Martinez, A ;
Pascual, MJ ;
Gratwohl, A ;
Prentice, HG ;
Black, C ;
Tyndall, A .
ANNALS OF THE RHEUMATIC DISEASES, 2001, 60 (06) :577-584
[3]
Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease [J].
Brodsky, RA ;
Petri, M ;
Smith, BD ;
Seifter, EJ ;
Spivak, JL ;
Styler, M ;
Dang, CV ;
Brodsky, I ;
Jones, RJ .
ANNALS OF INTERNAL MEDICINE, 1998, 129 (12) :1031-1035
[4]
Burt RK, 1999, ARTHRITIS RHEUM, V42, P2281, DOI 10.1002/1529-0131(199911)42:11<2281::AID-ANR4>3.0.CO
[5]
2-E
[6]
DRENKARD C, 1994, J RHEUMATOL, V21, P1067
[7]
Furst DE, 2001, ARTHRITIS RHEUM, V44, pS267
[8]
Predictors of radiographic joint damage in patients with early rheumatoid arthritis [J].
Jansen, LMA ;
van der Horst-Bruinsma, IE ;
van Schaardenburg, D ;
Bezemer, PD ;
Dijkmans, BAC .
ANNALS OF THE RHEUMATIC DISEASES, 2001, 60 (10) :924-927
[9]
Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate:: a randomised phase III trial [J].
Maini, R ;
St Clair, EW ;
Breedveld, F ;
Furst, D ;
Kalden, J ;
Weisman, M ;
Smolen, J ;
Emery, P ;
Harriman, G ;
Feldmann, M ;
Lipsky, P .
LANCET, 1999, 354 (9194) :1932-1939
[10]
McSweeney PA, 1999, ARTHRITIS RHEUM-US, V42, P2269, DOI 10.1002/1529-0131(199911)42:11<2269::AID-ANR2>3.0.CO